Overall these findings validate RNF5 as a drug target for neuroectodermal tumors, and Analog-1 as a promising small drug to progress towards full preclinical development, paving the way to future clinical trials for NB and melanoma patients. Here, RNF5 is linked to primitive neuroectodermal tumor.